Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Summary

RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients with metastatic melanoma that has not responded to previous treatment.

Timeline

Start

1998-09

Primary completion

—

Completion

2007-03

Drugs

Indications